Building on Jiangsu province's reputation as a leader in biomedicine and Suzhou's efforts to establish a world-class biopharmaceuticals and advanced medical devices cluster, Zhangjiagang is forging its own path in this growing industry, aiming for the 10-billion-yuan ($1.39 billion) milestone.
The city now hosts over 50 enterprises above designated size in the biomedicine and medical device sectors, with output projected to increase by 16.65 percent in 2024 compared to the previous year. Zhangjiagang has developed a strong position in medical consumables, particularly orthopedic implants. As one of the birthplaces of China's orthopedic device industry, Jinfeng town has become a major center, housing more than 110 high-end medical device companies. The park's output reached 898 million yuan in 2024, marking a 23.9 percent rise from the previous year.
Zhangjiagang has developed capabilities in biopharmaceuticals, biochemical diagnostic reagents, and medical aesthetics, backed by a network of specialized industrial parks and service platforms.
Looking forward, the city intends to emphasize high-value consumables, active pharmaceutical ingredients, advanced medical equipment, in vitro diagnostics, premium medical aesthetics, and synthetic biology. It aims to strengthen its expertise in orthopedic materials and implantable devices while developing unique capabilities in synthetic biology, aspiring to become a key competitor in China's biomedicine and medical device industry.
An aerial view of Zhangjiagang. [Photo/WeChat account: zhangjiagangfabu365]